Eli Lilly and Company· @EliLillyandCo · X·· 3 小时前精选AI 评分50
AI 导读
礼来在EASD2026上公布其选择性胰淀素激动剂与GIP/GLP-1受体激动剂在研复方的结果，在肥胖合并2型糖尿病成人中显示出减重和A1C降低的积极表现。该复方目前仍处于在研阶段，礼来未在帖文中披露具体数据。更多信息见 https://go.lilly.com/j8vyoc。
推荐理由
礼来在EASD2026公布的在研复方数据，可了解选择性胰淀素激动剂与GIP/GLP-1受体激动剂联用在肥胖合并2型糖尿病人群中的减重与降糖表现。
正文
Presented at #EASD2026, our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results in adults with obesity and type 2 diabetes: substantial weight loss and A1C reduction. Read more: https://go.lilly.com/j8vyoc
来源：Eli Lilly and Company · x.com